Can Aripiprazole Reverse SSRI-Induced Sexual Dysfunction?
Yes, aripiprazole can help reduce SSRI-induced sexual dysfunction and represents a viable augmentation strategy for patients experiencing this adverse effect. The evidence supports aripiprazole as an effective option for managing sexual dysfunction in patients on SSRIs, though it should be considered alongside other management approaches.
Evidence for Aripiprazole's Benefit
The FDA label for Abilify notes that when aripiprazole is combined with antipsychotics that have greater side-effect burdens, beneficial effects include "reduced weight gain, dyslipidemia, hyperprolactinemia, and sexual dysfunction" 1. While this specific statement refers to antipsychotic polypharmacy, the mechanism is relevant to SSRI-induced sexual dysfunction.
A direct comparison study demonstrated that aripiprazole augmentation in SSRI-treated patients with major depressive disorder showed no significant differences in adverse sexual events compared to bupropion augmentation 2. Importantly, the study noted that "both aripiprazole and bupropion could help reduce sexual dysfunction and fatigue in patients with MDD" 2. This 6-week randomized trial found aripiprazole augmentation achieved higher remission rates (55.4% vs 34.0%) than bupropion while maintaining comparable sexual tolerability 2.
Clinical Management Algorithm
When SSRI-induced sexual dysfunction occurs:
First-line approaches:
- For decreased libido: Switch to a non-serotoninergic antidepressant (bupropion, mirtazapine, moclobemide, agomelatine), reduce SSRI dose, or add bupropion or aripiprazole 3, 4
- For orgasm delay/anorgasmia: Dose reduction, "weekend holiday," switch to non-serotoninergic drug or fluvoxamine 3
- For erectile dysfunction: Switch to non-serotoninergic drug or add phosphodiesterase-5 inhibitors 3
Aripiprazole-specific considerations:
- Typical augmentation doses: 2-15 mg/day (based on dosing ranges in clinical trials 5)
- Monitor for akathisia (13% incidence in bipolar mania trials) 5
- Watch for restlessness (6% incidence) and extrapyramidal symptoms (5% incidence) 5
Mechanism and Rationale
Aripiprazole functions as a partial dopamine agonist, which may counteract the dopamine-suppressing effects of SSRIs that contribute to sexual dysfunction. SSRIs cause sexual dysfunction primarily through excessive serotonergic activity, which suppresses dopamine and nitric oxide pathways critical for sexual function 6, 4.
Important Caveats
The evidence base has limitations:
- The direct comparison study was open-label, not double-blinded 2
- Most data comes from augmentation studies in depression rather than studies specifically targeting sexual dysfunction
- Individual response varies considerably
Alternative strategies with stronger evidence:
- Switching to bupropion, mirtazapine, or moclobemide has the most consistent evidence for lower sexual dysfunction rates 4
- PDE5 inhibitors (sildenafil) have placebo-controlled evidence specifically for erectile dysfunction 7
- Dose reduction is often effective if depression remains controlled 3, 4
Practical Implementation
Start aripiprazole at 2-5 mg daily and titrate based on response and tolerability. Assess sexual function using structured questionnaires (like the Psychotropic-Related Sexual Dysfunction Questionnaire used in trials 2) rather than relying on spontaneous reports, as patients rarely volunteer this information 3, 8.
Monitor closely for:
- Akathisia and restlessness (common with aripiprazole) 5
- Improvement in sexual function within 2-4 weeks 2
- Depression symptom control
If aripiprazole causes intolerable akathisia or fails to improve sexual function after 4-6 weeks, consider switching the primary antidepressant to one with lower sexual dysfunction risk (bupropion, mirtazapine, moclobemide, agomelatine, or vortioxetine) 8, 4.